




SAPIENZA
UNIVERSITÀ DI ROMA

la Scienza a portata di mano



Comunicazione delle Scienze Biomediche

Prof.ssa Cristina Cerboni


Immunità e tumori




Anno Accademico 2025-2026

Il materiale presente in questo documento viene distribuito solamente per uso interno ed esclusivamente a scopo didattico.


The Cancer-Immunity Cycle



The cancer-immunity cycle with stimulatory and inhibitory factors




Immunità e tumori: le tre E



*Treg: regulatory T cells
MDSC: myeloid-derived suppressor cells
TAM: tumor-associated macrophages*

The immune system establishes a dynamic interaction with the tumour: **cancer immunoediting**



Le tre E

ELIMINAZIONE


EQUILIBRIO

EVASIONE


“The genetic damage that on the one hand leads to oncogenic outgrowth can also be targeted by the immune system to control malignancies”.

Schumacher and Schreiber, Science 2015

ELIMINAZIONE




Le cellule NK eliminano una cellula tumorale attraverso il *missing-self* (1) e l'*induced-self* (2)



il *missing-self* (1) è la perdita di inibizione (MHC-I);


l'*induced-self* (2) è una "super-attivazione" dovuta all'aumento di espressione di molecole attivatorie (MICA, ULBPs)

The principal mechanism of immune protection against tumors is killing of tumor cells by CD8+ CTLs



Gli antigeni tumorali

La generazione di antigeni tumorali



Chr, chromosome;
 ERV, endogenous retrovirus;
 INDEL, insertion or deletion;
 SNV, single-nucleotide variant

Quali tipi di antigeni tumorali conosciamo?

only expressed by the tumor
(one tumor type)


also found in other normal
cell types

only expressed by the tumor
(more tumor types)

Antigen type	Description	Examples of antigen type
Tumour-specific antigens ^{3,9} TSA	• Completely absent from normal host cells • Arise in cancer cells from oncogenic viral proteins or nonsynonymous somatic mutations	• HPV oncoproteins E6 and E7 (HPV-associated cancers of the cervix, anus and oropharynx)^{11,12} • Individual KRAS mutations (pancreatic, colon, lung and various other cancers)^{10,19}
Tumour-associated antigens ⁹ TAA	• Low levels of expression on normal host cells • Disproportionately expressed on tumour cells • Often result from genetic amplification or post-translational modifications • Can be selectively expressed by the cell lineage from which the cancer evolved	• ERBB2 (some breast cancers and various other cancers)¹⁵⁰ • Mesothelin (pancreatic cancer and mesothelioma)¹⁵⁹⁻¹⁶¹ • CD19 on B cell malignancies^{27,28}
Cancer/testis antigens ^{13,14} CTA (Shared TSA)	• Absent on normal adult cells, except in reproductive tissues (e.g. testes, fetal ovaries and trophoblasts) • Selectively expressed by various tumour types	• MAGE (various cancers)¹⁶² • NY-ESO-1 antigen (various cancers)¹⁶³



ANTIGENI TUMORALI UMANI (alcuni esempi)

- **Prodotti di geni amplificati o mutati** (HER-2/neu).
- **Prodotti di oncogeni o geni onco-soppressori** (Ras, Bcr-Abl, p53).
- **Prodotti di virus oncogeni** (E6 ed E7 del papilloma virus; EBNA-1 del virus di Epstein-Barr).
- **Antigeni tumorali/testicolari**: normalmente silenti nei tessuti normali (tranne testicolo e trofoblasto), ma espressi da molti tumori (MAGE).
- **Antigeni oncofetal**: espressi nei tessuti fetali in via di sviluppo e da molti tumori nell'adulto, ma non dai tessuti normali (CEA, AFP).
- **Antigeni di differenziazione tissutale** (tirosinasi dei melanociti, antigene prostatico specifico/PSA, CD10, CD20).
- **Glicolipidi e glicoproteine alterate** (MUC-1).



TANTIGEN:
Classification
of tumor
antigens

**Come si
identificano nuovi
antigeni tumorali?**



**L'importanza della
bioinformatica!**

Cancer whole exome sequencing




Mutations




Neoantigens

Estimate of the neoantigen repertoire in human cancers




Immunità adattativa


The principal mechanism of immune protection against tumors is killing of tumor cells by CD8+ CTLs




I linfociti T devono essere localizzati nel posto giusto!






Linfociti CD3+ INTRATUMORALI



Linfociti CD3+ PERITUMORALI



Tanti, di buona qualità e nel posto giusto: come la presenza dei linfociti T correla con una prognosi migliore nel cancro del colon-retto




Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome

Jérôme Galon,^{1,*†} Anne Costes,¹ Fatima Sanchez-Cabo,² Amos Kirilovsky,¹ Bernhard Mlecnik,² Christine Lagorce-Pagès,³ Marie Tosolini,¹ Matthieu Camus,¹ Anne Berger,⁴ Philippe Wind,⁴ Franck Zinzindohoué,⁵ Patrick Bruneval,⁶ Paul-Henri Cugnenc,⁵ Zlatko Trajanoski,² Wolf-Herman Fridman,^{1,7} Franck Pagès^{1,7†}

29 SEPTEMBER 2006 VOL 313 SCIENCE www.sciencemag.org

Tanti, di buona qualità e nel posto giusto




Immuno score: CD8+/CD45+RO+/GRZB+ in CT (center of the tumour) e IM (invasive margin)




Hot and cold tumors: the presence of immunogenic tumor antigens and the tumor's capacity to attract immune cells

Quantity and distribution of immune cells within a tumor have been proposed as broad measurements of tumor immunogenicity, with three typical scenarios being recognized:

- 1- inflamed tumors (“**hot**”, immune infiltration)
- 2- immune-excluded tumors (presence of T cells at the tumor margins but not in the tumor core)
- 3- immune-desert tumors (“**cold**”, no immune infiltration)




Defining ‘hot’, ‘altered’ and ‘cold’ immune tumors:
Immunoscore as a new approach for the classification of cancer



Immunoscore:
immune cell infiltrate

Trasformare un tumore “freddo” in uno “caldo”: l’immunoterapia!


Cold tumors



Nonimmunogenic tumor microenvironment

Combination therapies with agents that create immunogenic tumor microenvironment and immune checkpoint therapy

Hot tumors




Immunogenic tumor microenvironment

Immune checkpoint therapy and durable clinical benefit

(Science 03 Apr 2015: 348, 56-61)

The immune system establishes a dynamic interaction with the tumour: **cancer immunoediting**





Le tre E

ELIMINAZIONE

EQUILIBRIO

EVASIONE

Un tumore è costituito da diversi tipi di cellule...



...e da diversi microambienti

Quali sono le cellule infiammatorie nel microambiente tumorale che favoriscono lo sviluppo e la progressione tumorale?

- Macrofagi associati al tumore (TAM)



- Cellule dendritiche (DC)

- Mastociti

- Neutrofili

- Eosinofili

Cosa fanno?

- Inibiscono la risposta anti-tumorale


- Promuovono la proliferazione cellulare, la deposizione dello stroma, l'angiogenesi

- Inducono o aumentano il danno al DNA

I macrofagi associati al tumore (TAM)


anti-tumorali

M1 Macrophage



Function:
Proinflammatory activity
Microbial and tumoral activity
Tissue damage


M2 Macrophage



Function:
Anti-inflammatory activity
Phagocytosis capacity
Tissue regeneration and repair
Angiogenesis and immunomodulation
Tumor formation and progression


pro-tumorali

Il ruolo dei TAM nell'infiammazione e cancro



macrofagi associati al tumore (TAM)

Although cancer is described as a disease of genetic mutations, it is clear the important, but multifaceted role of the host.



Infiammazione e cancro: (alcune) evidenze a favore




Virchow, 1863

- Le malattie infiammatorie dell'intestino (colite ulcerosa, malattia di Crohn) sono associate ad un alto rischio di cancro del colon-retto. Individui con la colite ulcerosa hanno un rischio dieci volte maggiore di sviluppare un cancro del colon-retto, rispetto al resto della popolazione.
- L'esposizione cronica a sostanze irritanti che causano un'inflammazione dei bronchi (es., sigarette, asbesto, silice) è associata ad un elevato rischio di cancro del polmone.
- L'esposizione eccessiva ai raggi UV aumenta il rischio di melanoma.
- Molti tumori sono correlati ad una esposizione cronica ai patogeni (es., cancro dello stomaco ed *Helicobacter pylori*; epatocarcinoma e HCV; cancro della cervice e HPV).


Inductor	Inflammation	Cancer
Gut pathogens	Inflammatory bowel disease	Colorectal cancer
Tobacco smoke	Bronchitis	Bronchial lung cancer
<i>Helicobacter pylori</i>	Gastritis	Gastric cancer
Human papilloma virus	Cervicitis	Cervical cancer
Hepatitis B/C virus	Hepatitis	Hepatocellular carcinoma
Bacteria, gall bladder stones	Cholecystitis	Gall bladder cancer
Tobacco, genetics, alcohol	Pancreatitis	Pancreatic cancer
Epstein-Barr virus	Mononucleosis	Burkitt's lymphoma
Ultraviolet light	Sunburn	Melanoma
Asbestos fibers	Asbestosis	Mesothelioma
Gram-uropathogens	Schistosomiasis (Bilharzia)	Bladder cancer
Gastric acid, alcohol, tobacco	Esophagitis	Esophageal adenocarcinoma

Inflammation e cancro




Chronic inflammation associated with infections or autoimmune disease precedes tumor development and can contribute to it through induction of oncogenic mutations, genomic instability, early tumor promotion, and enhanced angiogenesis.

Chronic inflammation can promote malignant transformation



The immune system establishes a dynamic interaction with the tumour: **cancer immunoediting**








Le tre E

ELIMINAZIONE

EQUILIBRIO

EVASIONE



Alcuni meccanismi con cui i tumori sfuggono al riconoscimento da parte del sistema immunitario

Low immunogenicity	Tumor treated as self antigen	Antigenic modulation	Tumor-induced immune suppression	Tumor-induced privileged site
No peptide:MHC ligand No adhesion molecules No co-stimulatory molecules	Tumor antigens taken up and presented by APCs in absence of co-stimulation tolerize T cells	T cells may eliminate tumors expressing immunogenic antigens, but not tumors that have lost such antigens	Factors (e.g., TGF- β , IL-10, IDO) secreted by tumor cells inhibit T cells directly. Expression of PD-L1 by tumors	Factors secreted by tumor cells create a physical barrier to the immune system
 T cell CD8 CD28 LFA-1 TCR tumor	 T cell DC tumor	 T cell apoptosis tumor	 CTL Th1 Treg TGF-β IL-10 IDO PD-L1 tumor	 tumor

During the equilibrium phase tumor cell variants may emerge that

- (i) are no longer recognized by adaptive immunity (antigen loss variants or tumors cells that develop defects in antigen processing or presentation),
- (ii) become insensitive to immune effector mechanisms, or
- (iii) induce an immunosuppressive state within the tumor microenvironment.


HLA class I down-modulation as a tumor evasion strategy against CD8+ T cell recognition




HLA-I- prostate cancer, with HLA-I+ stroma and infiltrating cells

Frequency (%) of HLA-I altered phenotypes in invasive tumors


Evasione



Tumor Microenvironment




MDSC suppress anti-tumor activity through different mechanisms



La progressione neoplastica e la formazione delle metastasi dipendono dal microambiente

chemochine
citochine
fattori di crescita
recettori

Il microambiente è importante!



Il microambiente tumorale è un protagonista indispensabile del processo neoplastico, poiché favorisce la proliferazione, la sopravvivenza e la migrazione delle cellule tumorali.

Coussens LM and Werb Z Nature 2002

Il processo di formazione delle metastasi

1889 Stephen Paget
L'ipotesi "Seed and Soil" (Il seme e il terreno):

**Le metastasi si sviluppano solo se
il seme e il terreno sono compatibili!**



*In his paper, Paget analyzes 735 fatal cases of breast cancer, complete with autopsy, as well as many other cancer cases from the literature and argues that the distribution of metastases cannot be due to chance, concluding that although "the best work in pathology of cancer is done by those who... are studying the nature of the **seed**..." [the **cancer cell**], but the "observations of the properties of the **soil**" [the **secondary organ**] "may also be useful"...*

Seed and Soil

I semi vanno in tutte le direzioni, ma cresceranno solo quelli che cadranno dove il terreno gli è congeniale



Teoria postulata nel 1889 dal Dr. Stephen Paget: “**seed and soil**”

la cellula metastatica (**the seed**) necessita di un appropriato microambiente (**the soil**) per crescere e svilupparsi in un'altra regione corporea diversa da quella di origine.

Le cellule tumorali (**seed**) hanno affinità per alcuni organi (**soil**).
Si formano metastasi solo quando **seed & soil** sono compatibili

I fatti sono...

- 1. Gli organi bersagliati dalle metastasi sono spesso sempre gli stessi**
- 2. I reni, che ricevono il 25% della gittata cardiaca, sono raramente sede di metastasi**
- 3. Il miocardio, con tutto il sangue che riceve... non è quasi mai sede di metastasi**
- 4. Non sempre le metastasi seguono “regole anatomiche”**

Quindi i tumori hanno “particolari” preferenze d'organo non sempre spiegabili su base anatomica

Organotropismo delle localizzazioni metastatiche



localizzazione preferenziale delle
metastasi in determinati organi

Metastatizzazione preferenziale






Figure 14-42 The Biology of Cancer (© Garland Science 2007)



“Immunoediting” del tumore: le 3 E


Eliminazione

When tumors arise in a tissue a number of immune cells can recognize and eliminate them




Equilibrio

Variant tumor cells arise that are more resistant to being killed




Evasione

Eventually, one variant may escape the killing mechanism, or recruit regulatory cells to protect it, and so spread unchallenged



Immunità e tumori




THE IMMUNE SYSTEM IS A “DOUBLE-EDGED SWORD”

- It can destroy tumor cells, and yet paradoxically also promote and sustains cancer.
- The complexity of the immune system-cancer relationship depends on tumor cellular origin, mode of transformation, anatomic location, stromal response, cytokine production profile, inherent immunogenicity....etc.


*Treg: regulatory T cells
MDSC: myeloid-derived suppressor cells
TAM: tumor-associated macrophages*

Le proprietà di un tumore

2001



2011



10 anni dopo emergono nuove proprietà...